Skip to main content Skip to search Skip to main navigation
News: Europe

European Commission: Steps to Ensure the Availability of Medicines

On 24 October 2023, the European Commission adopted steps to prevent drug shortages and increase the security of supply in the European Union.

Following supply disruptions in the EU lately, the Commission, with the help of other authorities and associations, has developed a set of measures to prevent critical shortages of key medicines in the future.

In preparation, the European Health Emergency Preparedness and Response Authority (HERA) and the European Medicines Agency (EMA) have already identified the key antibiotics expected to face shortages during the winter months.

In addition, the following measures have been and are being taken:

  • a voluntary solidarity mechanism allows member states to share medicines among themselves
  • a Union list of critical medicines will be established to identify weak links in the supply chain
  • regulatory flexibilities to ensure rapid access to medicines
  • EU guidelines on drug procurement to increase security of supply
  • a joint procurement of antibiotics and respiratory therapeutics on EU level for the next winter

Regulatory flexibilities for essential medicines are expected to be a key element. This is specifically aimed to accelerate the approval and introduction of alternative medicines, to increase production and approval of alternative suppliers, to temporarily extend the shelf life of products, and to allow for the redistribution of medicines between member states.

The European Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) has provided further insight into how these flexibilities will be applied this winter. Competent authorities will decide on a case-by-case basis whether recommendations will be implemented.

To secure the long-term supply of medicines, the Commission plans to establish a Critical Medicines Alliance that will focus on particularly important medicines. This alliance will include measures to diversify manufacturing and modernize supply chains. It is expected to be launched early next year.

The availability of medicines worldwide requires international cooperation and partnerships, including with third countries.


Source:

EC: Press release

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic Updates Guidance on GMP Compliance of Foreign Manufacturers

Swissmedic has revised its guidance document “GMP compliance by foreign manufacturers”. The new Version 7.0 has been valid since 7 September 2026. In particular, it introduces new provisions for demonstrating the GMP compliance of manufacturers inspected by the US FDA. 
Read more
Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic Updates Requirements for Cooperation with Pre-Wholesalers

Swissmedic has revised its Technical Interpretation “Market release and distribution in cooperation with a pre-wholesaler”. The document addresses market release and distribution where a Marketing Authorisation Holder works with a pre-wholesaler (logistics and distribution service provider).
Read more
News: Europe

IPEC Updates Two Guides on Pharmaceutical Excipients

The IPEC Federation has updated two key guides on pharmaceutical excipients. The IPEC Composition Guide for Pharmaceutical Excipients (Version 3, 2026) describes an approach for manufacturers to establish excipient composition profiles. The revised version now covers biotechnology- and fermentation-derived excipients, provides further details on component types and physicochemical characterisation, and includes an example composition profile template.
Read more
Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Artificial intelligence is becoming increasingly important in GMP-regulated environments, presenting companies with new regulatory challenges. This article summarizes the latest regulatory developments, introduces a validation framework based on the FDA's seven-step model, and outlines initial practical experience with AI/ML validation.

Read more
Question of the Week | GMP-Verlag

What are the General Requirements for Standard Documents?

Here's the answer:
Read more
News: Europe

EDQM: Revised Guidance on Sister File Applications

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has revised its Guidance on applications for “sister files” (PA/PH/CEP (09) 141). The revision is intended to support consistent application of the procedure and provide greater clarity on the classification and assessment of the corresponding CEP applications.
Read more
Previous
Next